Investing
The funds will be used to grow the company's engineering and commercial workforce, enhance product development, and accelerate integration with payers and providers.
The funds will be used to improve the company's flight cadence and expand its pharmaceutical lab capabilities.
Plexāā, maker of the Bloom medical device for breast surgery, scores $4.5 million in funding.
The spin-off company is expected to rake in almost $2 billion in revenue this year.
The Polyphonic AI Fund for Surgery will invest in and provide mentorship to AI-enabled platforms aiming to advance surgical innovation.
The company offers mental healthcare for children and their families and will use the funds to expand its reach.
The company offers an AI-enabled workflow automation platform for administrative tasks pertaining to specialty medications.
The company will use the funds to hasten product development, engineering and go-to-market efforts to meet market demand.
The company will use the funds to advance its AI-enabled robotic platform for cataract and other eye surgeries, with plans to begin human clinical trials this year.
The Series E funding comes four months after the company secured $250 million in a Series D round.